- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 September 2023 December 2023 PBAC Meetings - (PDF 0.9MB)
- Public Summary Document (PSD) July 2023 September 2023 December 2023 PBAC Meetings - (Word 0.5MB)
Patisiran – July 2023
Patisiran: Solution concentrate for I.V. infusion 10 mg in 5 mL; Onpattro® - July 2023 – September 2023 PBAC meetings
Last updated
5 April 2024
